# Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome

> **NCT05521438** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Quoin Pharmaceuticals** · enrollment: 30 (estimated)

## Conditions studied

- Netherton Syndrome

## Interventions

- **DRUG:** QRX003-2% Lotion
- **DRUG:** QRX003-4% Lotion QAM
- **DRUG:** Vehicle
- **DRUG:** QRX003-4% Lotion BID

## Key facts

- **NCT ID:** NCT05521438
- **Lead sponsor:** Quoin Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-23
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05521438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05521438, "Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT05521438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*